Variable | No BRCA founder mutation (n = 440) | BRCA1 founder mutation (n = 43)† | P (BRCA1 versus no founder mutation)* | BRCA2 founder mutation (n = 14)† | P (BRCA2 versus no founder mutation)* |
---|---|---|---|---|---|
Age at diagnosis (years) | |||||
< 50 | 135 (31%) | 30 (70%) | < 0.0001 | 4 (29%) | NS |
≥ 50 | 305 (69%) | 13 (30%) | 10 (71%) | ||
Tumor size | |||||
T1 | 324 (74%) | 29 (67%) | NS | 8 (57%) | NS |
T2 | 97 (22%) | 11 (26%) | 4 (29%) | ||
Unknown | 19 (4%) | 3 (7%) | 2 (14%) | ||
Nodal involvement | |||||
Present | 149 (34%) | 18 (42%) | NS | 6 (43%) | NS |
Absent | 262 (60%) | 23 (53%) | 6 (43%) | ||
Unknown | 29 (6%) | 2 (5%) | 2 (14%) | ||
Estrogen receptor | |||||
Positive | 197 (45%) | 6 (14%) | < 0.0001 | 7 (50%) | NS |
Negative | 98 (22%) | 27 (63%) | 3 (21%) | ||
Unknown | 145 (33%) | 10 (23%) | 4 (29%) | ||
Chemotherapy | |||||
Yes | 156 (35%) | 24 (56%) | 0.02 | 7 (50%) | NS |
No | 257 (58%) | 17 (40%) | 7 (50%) | ||
Unknown | 27 (10%) | 2 (4%) | 0 (0%) | ||
Tamoxifen | |||||
Yes | 190 (43%) | 10 (23%) | 0.01 | 9 (64%) | NS |
No | 203 (46%) | 30 (70%) | 5 (36%) | ||
Unknown | 47 (11%) | 3 (7%) | 0 (0%) |